GENE ONLINE|News &
Cartesian’s Off-the-shelf RNA Therapy for Myeloma Enters Clinical Trials
Regenerative medicine for cancer is transitioning from patient-derived/ autologous immune cells to off-the-shelf immune-cell therapy to ensure standardised quality and quantity of engineered cells which can be expanded to treat multiple patients with repeat dosing.
GO Prime with only $1.49 now
LATEST
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
